Ketamine Effects on CNS Responses Assessed with MEG/EEG in a Passive Auditory Sensory-gating Paradigm: an Attempt for Modelling Some Symptoms of Psychosis in Man
Overview
Affiliations
Disturbances in integrative function have been consistentLy described in psychotic disorder; for instance, prepulse inhibition of the startle reflex (startle-PPI) which is a marker of sensory gating, is deficient in persons with schizophrenia. The N-methyl-D-aspartate antagonist ketamine produces in control subjects a spectrum of neurobehavioural symptoms like encountered in schizophrenia, and disrupts startle-PPI in animals. In the present study, we investigated in 12 healthy subjects whether ketamine would reduce sensory-gating in auditory responses at doses which produce psychotic symptoms. In a double-blind, crossover design loading doses of 0.024, 0.081 and 0.27 mg/kg or saline were employed, followed by maintenance infusion for 120 min. A passive paradigm has been developed which consisted in tone bursts, preceded or not by a (near-threshold) click at intervals of 100 ms or 500 ms. Brain electromagnetic activity imaging of the responses to sound stimuli has been carried out by way of a 148-channel magnetoencephalography-system. Actual evoked response amplitudes and underlying equivalent current dipole strengths have been compared to multi-electrode evoked potentials from the scalp. A click stimulus is capable to inhibit test responses under placebo at the 100 ms interval. During maintenance infusion of ketamine at steady-state (for >30 min) after 0.27 mg/kg, no such amplitude changes were observed anymore (p <0.05) and under these circumstances significant increases in Brief Psychiatric Rating scale and Scale for the Assessment of Negative Symptoms scores were evidenced (p < 0.001). Intermediate effects have been observed when the dose was lowered to 0.081 mg/kg. The present results have shown that ketamine may induce a psychotic-like clinical state associated with gating deficits in healthy subjects.
de la Salle S, Choueiry J, McIntosh J, Bowers H, Ilivitsky V, Knott V Psychopharmacology (Berl). 2022; 239(7):2155-2169.
PMID: 35348805 DOI: 10.1007/s00213-022-06090-z.
Beck K, Hindley G, Borgan F, Ginestet C, McCutcheon R, Brugger S JAMA Netw Open. 2020; 3(5):e204693.
PMID: 32437573 PMC: 7243091. DOI: 10.1001/jamanetworkopen.2020.4693.
Potential Mechanisms for the Ketamine-Induced Reduction of P3b Amplitudes.
Rosburg T, Schmidt A Front Behav Neurosci. 2019; 12:308.
PMID: 30618662 PMC: 6297878. DOI: 10.3389/fnbeh.2018.00308.
Haaf M, Leicht G, Curic S, Mulert C Curr Pharm Biotechnol. 2018; 19(4):293-307.
PMID: 29929462 PMC: 6142413. DOI: 10.2174/1389201019666180620112528.
Holliday W, Gurnsey K, Sweet R, Teichert T J Psychiatry Neurosci. 2018; 43(3):182-193.
PMID: 29688874 PMC: 5915239.